Long-term safety, tolerability, and efficacy of efgartigimod in patients with generalized myasthenia gravis: Concluding analyses from the ADAPT+ study

Authors
Category Primary study
JournalJournal of the neurological sciences
Year 2023
This article has no abstract
Epistemonikos ID: 8fed651badc3ab2309ba9a13732c0788f5f5edc1
First added on: Feb 29, 2024